<i>CDK12</i> Deficiency and the Immune Microenvironment in Prostate Cancer
Tamara L. Lotan, Emmanuel S. Antonarakis
Abstract
Abstract CDK12 inactivation in prostate cancer is associated with tandem genomic duplications that may generate fusion-associated neoantigens and elicit immune responses amenable to checkpoint blockade. In the first study to comprehensively characterize the T-cell immune microenvironment of CDK12-deficient prostate cancers, subsets of immunosuppressive CD4+FOXP3− T cells were increased compared with CDK12-proficient controls. See related article by Rescigno et al., p. 566
Topics & Concepts
Immune systemProstate cancerProstateTumor microenvironmentCancer researchImmune checkpointMedicineCancerBlockadeImmunologyFOXP3BiologyImmunotherapyInternal medicineReceptorCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesProstate Cancer Treatment and Research